Focus: Cadence Neuroscience is a medical device company headquartered in Redmond, WA, focused on implantable device therapy for epilepsy. The company operates in the neurology segment with a limited public product footprint.
Profile data last refreshed 10h ago · AI intelligence enriched 2w ago
No open roles listed right now. Follow Cadence Neuroscience to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Post-loss-of-exclusivity generic oral contraceptive; legacy asset generating minimal strategic value.
Help build intelligence for Cadence Neuroscience
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Cadence Neuroscience's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Post-LOE branded oral contraceptive; mature portfolio asset with declining relevance.
Post-LOE generic oral contraceptive; legacy asset with limited commercial momentum.
Pre-launch oral contraceptive; potential near-term marketing opportunity but crowded category.
NDA-approved oral contraceptive approaching loss of exclusivity; revenue cliff imminent.
Post-LOE generic oral contraceptive; mature portfolio asset with structural decline.
Post-LOE generic oral contraceptive; legacy asset with minimal differentiation.
Post-LOE generic oral contraceptive; legacy asset with structural revenue decline.
9 discontinued, 4 duplicate formulations not shown
No open positions listed yet.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo